Division of Astellas Pharma Inc.
Latest From Mitobridge Inc.
The venture capitalist builds biotechs from scratch and with this latest fund, MPM is looking to add to its sector-leading record of 49 FDA-approved drugs and over 100 IPOs and acquisitions.
Astellas builds on a 2013 collaboration by acquiring Mitobridge. Ardelyx is partnering with Kyowa Hakko Kirin to bring tenapanor to market in Japan. Meanwhile, Depomed, Xoma and Bristol all offload programs before the end of the year.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance or Financing. This month’s column covers deals announced in November 2017.
A review of biopharma start-up deal-making and financing activity from July through September 2017, based on data from Strategic Transactions, showed that fundraising declined 18% from the previous quarter, however the number of acquisitions doubled to eight.
- Drug Discovery Tools
- Therapeutic Areas
- Hepatic (Liver)
- Metabolic Disorders
- Musculoskeletal & Connective Tissue Disorders
- Neurology, Nervous System
- Renal System
- North America
- Parent & Subsidiaries
- Astellas Pharma Inc.
- Senior Management
Kazumi Shiosaki, PhD, Pres. & CEO
Mike Patane, PhD, CSO
Lisa Paborsky, PhD, SVP, Corp. Dev. & Strategic Relations
- Contact Info
Phone: (617) 401-9100
1030 Massachusetts Ave.
Cambridge, MA 02138